个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共40条记录   Anaplastic thyroid carcinoma arising from a calcified thyroid mass [作者：Kim, SJ; Kwak, JY; Hong, SW; Kim, EK; Kim, MJ; Park, SH; Son, EJ; Park, CS; Chung, WY,期刊：Journal of clinical oncology, 页码：3800-3802 , 文章类型： Article，,卷期：2008年26-22] Capecitabine-induced coronary vasospasm [作者：Goldsmith, YB; Roistacher, N; Baum, MS,期刊：Journal of clinical oncology, 页码：3802-3804 , 文章类型： Article，,卷期：2008年26-22] Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia [作者：Kesari, S; Akar, S; Saad, A; Drappatz, J; Koralnik, IJ; DeAngelo, DJ,期刊：Journal of clinical oncology, 页码：3804-3807 , 文章类型： Article，,卷期：2008年26-22] Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? [作者：Adam, R; de Haas, RJ; Wicherts, DA; Aloia, TA; Delvart, V; Azoulay, D; Bismuth, H; Castaing, D,期刊：Journal of clinical oncology, 页码：3672-3680 , 文章类型： Article，,卷期：2008年26-22] Purpose For patients with colorectal liver metastases (CLM), regional lymph node (RLN) involvement is one of the worst prognostic factors. The objective of this study was to evaluate the ability of a multidisciplinary ap... Preschool as palliative care [作者：Ross, ME; Hicks, J; Furman, WL,期刊：Journal of clinical oncology, 页码：3797-3799 , 文章类型： Article，,卷期：2008年26-22] Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A children's oncology group pilot study [作者：Raetz, EA; Cairo, MS; Borowitz, MJ; Blaney, SM; Krailo, MD; Leil, TA; Reid, JM; Goldenberg, DM; Wegener, WA; Carroll, WL; Adamson, PC,期刊：Journal of clinical oncology, 页码：3756-3762 , 文章类型： Article，,卷期：2008年26-22] Purpose To determine the tolerability and serum concentration of epratuzumab, a humanized monoclonal antibody targeting CD22, administered alone and in combination with reinduction chemotherapy in children with relapsed ... Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: A multicenter, phase II trial of the Swiss Group for Clinical Cancer Research [作者：Koeberle, D; Saletti, P; Borner, M; Gerber, D; Dietrich, D; Caspar, CB; Mingrone, W; Beretta, K; Strasser, F; Ruhstaller, T; Mora, O; Herrmann, R,期刊：Journal of clinical oncology, 页码：3702-3708 , 文章类型： Article，,卷期：2008年26-22] Purpose To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in pat... Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: Results from a phase III randomized trial [作者：Cella, D; Li, JZ; Cappelleri, JC; Bushmakin, A; Charbonneau, C; Kim, ST; Chen, I; Motzer, RJ,期刊：Journal of clinical oncology, 页码：3763-3769 , 文章类型： Article，,卷期：2008年26-22] Purpose In an international, randomized phase III trial, sunitinib demonstrated statistically significant efficacy over interferon alfa (IFN-alpha) as first-line therapy in patients with metastatic renal cell carcinoma (... Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [作者：Azad, NS; Posadas, EM; Kwitkowski, VE; Steinberg, SM; Jain, L; Annunziata, CM; Minasian, L; Sarosy, G; Kotz, HL; Premkumar, A; Cao, L; McNally, D; Chow, C; Chen, HX; Wright, JJ; Kohn, EC,期刊：Journal of clinical oncology, 页码：3709-3714 , 文章类型： Article，,卷期：2008年26-22] Purpose Sorafenib inhibits Raf kinase and vascular endothelial growth factor (VEGF) receptor. Bevacizumab is a monoclonal antibody targeted against VEGF. We hypothesized that the complementary inhibition of VEGF signalin... Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy [作者：Langendijk, JA; Doornaert, P; Verdonck-de Leeuw, IM; Leemans, CR; Aaronson, NK; Slotman, BJ,期刊：Journal of clinical oncology, 页码：3770-3776 , 文章类型： Article，,卷期：2008年26-22] Purpose To investigate the impact of treatment-related toxicity on health-related quality of life (HRQoL) among patients with head and neck squamous cell carcinoma treated with radiotherapy either alone or in combination... A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [作者：Ashworth, A,期刊：Journal of clinical oncology, 页码：3785-3790 , 文章类型： Article，,卷期：2008年26-22] Cancer cells frequently harbor defects in DNA repair pathways, leading to genomic instability. This can foster tumorigenesis but also provides a weakness in the tumor that can be exploited therapeutically. Tumors with co... Phase II stopping rules that employ response rates and early progression [作者：Goffin, JR; Tu, DS,期刊：Journal of clinical oncology, 页码：3715-3720 , 文章类型： Article，,卷期：2008年26-22] Purpose Phase II oncology trials traditionally have used response rate (RR) as the primary end point, but newer targeted agents require the consideration of alternative end points. High rates of early progressive disease... Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? [作者：Dodd, LE; Korn, EL; Freidlin, B; Jaffe, CC; Rubinstein, LV; Dancey, J; Mooney, MM,期刊：Journal of clinical oncology, 页码：3791-3796 , 文章类型： Article，,卷期：2008年26-22] Progression-free survival is an important end point in advanced disease settings. Blinded independent central review (BICR) of progression in randomized clinical trials has been advocated to control bias that might resul... Anthracycline cardiotoxicity: From bench to bedside [作者：Gianni, L; Herman, EH; Lipshultz, SE; Minotti, G; Sarvazyan, N; Sawyer, DB,期刊：Journal of clinical oncology, 页码：3777-3784 , 文章类型： Review，,卷期：2008年26-22] Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investiga... Survival end point reporting in randomized cancer clinical trials: A review of major journals [作者：Mathoulin-Pelissier, S; Gourgou-Bourgade, S; Bonnetain, F; Kramar, A,期刊：Journal of clinical oncology, 页码：3721-3726 , 文章类型： Article，,卷期：2008年26-22] Purpose Several publications showed that the standards for reporting randomized clinical trials (RCTs) might not be entirely suitable. Our aim was to evaluate the reporting of survival end points in cancer RCTs.Methods A... Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: Phase II trial (E8296) of the eastern cooperative oncology group (vol 22, pg 4495, 2004) [作者：Armanios, M; Xu, RH; Forastiere, AA; Haller, DG; Kugler, JW; Benson, AB,期刊：Journal of clinical oncology, 页码：3819-3819 , 文章类型： Correction，,卷期：2008年26-22]